European Union - English - EMA (European Medicines Agency)

sandoz gmbh - pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesothelioma pemetrexed sandoz in combination with cisplatin is indicated for the treatment of chemotherapy naive patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer pemetrexed sandoz in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sandoz is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed sandoz is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - pregabalin - anxiety disorders; epilepsy - antiepileptics, - epilepsypregabalin sandoz gmbh is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.generalised anxiety disorderpregabalin sandoz gmbh is indicated for the treatment of generalised anxiety disorder (gad) in adults.

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - aripiprazole - schizophrenia; bipolar disorder - psycholeptics - aripiprazole sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. aripiprazole sandoz is indicated for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. aripiprazole sandoz is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in bipolar i disorder in adolescents aged 13 years and older.,

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - ibandronic acid - breast neoplasms; neoplasm metastasis; fractures, bone - drugs for treatment of bone diseases, bisphosphonates - ibandronic acid sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.,

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - pregabalin - anxiety disorders; neuralgia; epilepsy - antiepileptics, - neuropathic painpregabalin sandoz is indicated for the treatment of peripheral and central neuropathic pain in adults.epilepsypregabalin sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.generalised anxiety disorderpregabalin sandoz is indicated for the treatment of generalised anxiety disorder (gad) in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - piperacillin monohydrate 4.198 g equivalent to piperacillin sodium 4.2531g and 4.0g piperacillin;  ;  ; tazobactam 0.5 g equivalent to tazobactam sodium 0.54733 g - powder for injection - 4 g/0.5 g - active: piperacillin monohydrate 4.198 g equivalent to piperacillin sodium 4.2531g and 4.0g piperacillin     tazobactam 0.5 g equivalent to tazobactam sodium 0.54733 g - indicated for the treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated) 3. intra-abdominal infections 4. skin and skin structure infections 5. bacterial septicaemia 6. gynaecological infections 7. bacterial infections in neutropenic patients. full therapeutic doses of piptaz sandoz plus an aminoglycoside should be used. 8. bone and joint infections 9. polymicrobic infections: piptaz sandoz is indicated for polymicrobic infections including those where aerobic and anaerobic organisms are suspected (intra-abdominal, skin and skin structure, upper and lower respiratory tract, gynaecological). children under the age of 12 years in hospitalised children aged 2 to 12 years, piptaz sandoz is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - calcium carbonate 1500 mg - eq. calcium 600 mg; cholecalciferol 0,01 mg - effervescent tablet - 600 mg - 400 iu - cholecalciferol 0.01 mg; calcium carbonate 1500 mg - calcium, combinations with vitamin d and/or other drugs

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - calcium lactogluconate 1132 mg - eq. calcium 149,7 mg; calcium carbonate 875 mg - eq. calcium 350,3 mg - effervescent tablet - 500 mg - calcium carbonate 300 mg; calcium gluconolactate 2940 mg - calcium carbonate; a12aa06 calcium lactate gluconate

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - calcium gluconolactate 3326 mg - eq. calcium 440 mg; calcium carbonate 150 mg - eq. calcium 60 mg - oral powder - 500 mg - calcium gluconolactate 3400 mg; calcium carbonate 150 mg - calcium carbonate; a12aa06 calcium lactate gluconate

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - calcium carbonate 2500 mg - eq. calcium 1000 mg; cholecalciferol 880 iu - eq. vitamin d3 0,022 mg - chewable tablet - 1000 mg - 880 iu - calcium carbonate 2500 mg; cholecalciferol 880 iu - calcium, combinations with vitamin d and/or other drugs